KRAS and neoplasm: Ten out of eleven LGSOC tumors had variants identified in NRAS (27%), ERBB2 (27%) and sporadically in BAP1, KRAS, CDKN2A and BRAF. Six out of seven EOC tumors harbored variants in TP53, AKT1, PIK3CA, PTEN, KRAS, CCND1 and CTNNB1. In three EOC tumors multiple variants were detected (one tumor with six variants, another had 3 variants and a third had two variants).